The Detection of Cancer in Augmented Breast by Positron Emission Tomography.
10.4048/jkbcs.1999.2.1.44
- Author:
Dong Young NOH
1
;
Han Sung KANG
;
Ik Jin YUN
;
Ji Soo KIM
;
June Key CHUNG
;
Dong Soo LEE
;
Myung Chul LEE
;
Yeo Kyu YOUN
;
Seung Keun OH
;
Kuk Jin CHOE
Author Information
1. Department of Surgery, Seoul National University, College of medicine, Korea.
- Publication Type:Original Article
- Keywords:
FDG-PET;
breast cancer;
augmentation mammoplasty
- MeSH:
Axilla;
Breast Neoplasms;
Breast*;
Diagnosis;
Electrons*;
Female;
Glucose;
Humans;
Lymph Nodes;
Mammaplasty;
Mammography;
Mass Screening;
Metabolism;
Paraffin;
Positron-Emission Tomography*;
Prognosis;
Silicones;
Ultrasonography
- From:Journal of Korean Breast Cancer Society
1999;2(1):44-50
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
As breast cancer in patients who have undergone augmentation mammoplasty is usually detected late, prognosis is worse than it would otherwise be. Mammography has led to remarkable in the diagnosis of breast cancer, but didnot so in cancer arising from augmented breasts. FDG-PET, which uses fluorine-18-fluorodeoxy glucose (FDG), a glucose non-metabolized analogue , is able to detect breast cancer which shows more active rates of glucose metabolism. Cancer in a radioopaque dense breast, such as breast with silicone- or paraffin-augmentation and is not found by mammography, might be detected by FDG-PET. We tried to find out diagnostic efficienty of FDG-PET in detecting breast cancer with augmented breast. Between June 1995 and November 1997, eight patients had a history of breast augmentation with silicone or paraffin. Although most of them were examined at local clinic by physical exam, mammography or ultrasonography before visiting our hospital, definitive diagnosis could not be made. One patients wanted both breasts augmentsed with paraffin to be removed, and PET evaluated a total of nine lesions with pathological confirmation. As a result, the mammography detected the breast cancer in only one out of three malignancies, and ultrasonography made false positive result in one patient in augmented breast. In contrast, PET scan predicted all of malignancies and five out of six benign lesions precisely. Two of three breast cancers had axillary FDG uptake interpreted as consistent with metastatic involvement, and in one case with cancer of negative axillary lymph node involvement there was no FDG uptake in the axilla, which were correlated to pathologic finding. Although its high cost made the use of PET as a screening test for all augmented breast not feasible, it would, however, be the best diagnostic choice if other methods failed.
